Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage biopharmaceutical company focused on developing products to improve survival and/or quality of life for patients who have an unmet medical need condition for which there are few or no therapeutic options, has released update information regarding its clinical programs. Specifically, the updates provided information regarding enrollment for the programs. According to the announcement, PCSA’s PCS12852 program concluded enrollment a month ahead of schedule; the company anticipates that stats on gastric emptying, safety and GEBT data will be available by the end of October with full topline data expected before year end. The company’s PCS6422 program launched a new site to accelerate enrollment, with important data on de novo formation of DPD in October. Both new sites and new geographic areas have been added for the PCS499 program. “Recruiting for studies of very rare diseases like ulcerative necrobiosis lipoidica can be challenging,” said Processa Pharmaceuticals chief development officer Sian Bigora in the press release. “We are encouraged by the results of our multifaceted campaigns to increase the awareness and opportunities for patients to participate in our trial and are hopeful that these will continue to increase the number of patients in screening and enrollment. We have seen an increased willingness of patients to travel, potentially due to lower concerns about COVID. . . . We are also very encouraged by the rapid enrollment in PCS12852. This reminds us of the extraordinarily limited treatment options for gastroparesis and that patients are looking for alternative options to treat this condition. We continue to advance our clinical programs and with the expectation of important data from these programs in late 2022, each program will move further in the clinical development towards NDA submissions.”
To view the full press release, visit https://ibn.fm/bhs30
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include next-generation Capecitabine PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
